Immunogen Inc (NASDAQ:IMGN)
| 16.50 Real-Time Quote |  +0.12 / +0.73%Today’s Change | 10.85 Today|||52-Week Range 18.83 | +29.41% Year-to-Date |
Latest IMGN News | Press Releases
| Why ImmunoGen Is a Buy Right Now? Jun 14 / MotleyFool.com | A Trio of Cancer Immunotherapy Innovators Jun 14 / MotleyFool.com |
Today’s Trading
| Previous close | 16.38 |
| Today’s open | 16.50 |
| Day’s range | 16.49 - 16.50 |
| Volume | 4,925 |
| Average volume (3 months) | 711,675 |
| Market cap | $1.4B |
| Dividend yield | -- |
Data as of 9:42am ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | -11.76% |
| Earnings growth (this year) | +4.22% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | -15.27% |
| P/E ratio | NM |
| Price/Sales | 78.61 |
| Price/Book | 15.18 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GEVASynageva Biopharma C... | 0.00 | 0.00% |
| AEGRAegerion Pharmaceuti... | -0.62 | -0.97% |
| ITMNInterMune Inc | 0.00 | 0.00% |
| MNTAMomenta Pharmaceutic... | -0.06 | -0.42% |
Data as of 9:41am ET, 06/19/2013
Financials
| Next reporting date | August 8, 2013 |
| EPS forecast (this quarter) | -$0.30 |
| Annual revenue (last year) | $16.4M |
| Annual profit (last year) | -$73.3M |
| Net profit margin | -448.24% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Daniel M. Junius |
Chief Financial Officer, Treasurer & Executive VP Gregory D. Perry |
Corporate headquarters Waltham, Massachusetts |
Forecasts
